Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.50 |
| ▸ | MOK | Q9UQ07 | 7/20 | 0.48 |
| ▸ | METAP2 | P50579 | 1/20 | 0.45 |
| ▸ | CYP2A13 | Q16696 | 5/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.38 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.38 |
| ▸ | FEN1 | P39748 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19475290 | 0.86 | MOK (0.52) | L3MBTL1RAB9ANPC1PAX8MOK | |
| SCHEMBL19475395 | 0.84 | MOK (0.66) | MOKMAPTKDM4ELMNATDP1 | |
| SCHEMBL19475494 | 0.81 | MOK (0.76) | MOK | |
| SCHEMBL19475304 | 0.80 | MOK (0.73) | MOKKDM4ELMNAPOLB | |
| SCHEMBL14988278 | 0.72 | NCF1 (0.53) | HTTKDM4EMAP4K4 | |
| SCHEMBL19475283 | 0.72 | MOK (0.75) | MOK | |
| SCHEMBL19475336 | 0.69 | MOK (0.67) | L3MBTL1RAB9ANPC1MOKMAPT | |
| SCHEMBL19475402 | 0.69 | HAVCR2 (0.55) | RAB9ANPC1MOKMAPTHTT | |
| SCHEMBL31590658 | 0.69 | MOK (0.55) | MOKCYP2A13KDM4E | |
| SCHEMBL27253776 | 0.67 | L3MBTL1 (1.00) | L3MBTL1RAB9ANPC1PAX8METAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11192859-B2 | Quinoline compounds as modulators of RAGE activity and uses thereof | UNIV NEW YORK (US) | 2021-12-07 | — | — | US | disclosed |
| US-11192859-B2 | Quinoline compounds as modulators of RAGE activity and uses thereof | UNIV NEW YORK (US) | 2021-12-07 | — | — | US | disclosed |
| US-20190194136-A1 | QUINOLINE COMPOUNDS AS MODULATORS OF RAGE ACTIVITY AND USES THEREOF | UNIV NEW YORK (US) | 2019-06-27 | — | — | US | disclosed |
| US-20190194136-A1 | QUINOLINE COMPOUNDS AS MODULATORS OF RAGE ACTIVITY AND USES THEREOF | UNIV NEW YORK (US) | 2019-06-27 | — | — | US | disclosed |
| WO-2017184547-A1 | QUINOLINE COMPOUNDS AS MODULATORS OF RAGE ACTIVITY AND USES THEREOF | NEW YORK UNIVERSITY (US) | 2017-10-26 | — | — | WO | disclosed |
| WO-2017184547-A1 | QUINOLINE COMPOUNDS AS MODULATORS OF RAGE ACTIVITY AND USES THEREOF | NEW YORK UNIVERSITY (US) | 2017-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190194136-A1 | QUINOLINE COMPOUNDS AS MODULATORS OF RAGE ACTIVITY AND USES THEREOF | AGER, HMGB1, GPR119 | L3MBTL1 2976/4885RAB9A 1174/4885NPC1 3452/4885 |
| US-11192859-B2 | Quinoline compounds as modulators of RAGE activity and uses thereof | AGER, HMGB1, GPR119 | L3MBTL1 2976/4885RAB9A 1174/4885NPC1 3452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.